New: Introducing the Finviz Crypto Map

Learn More

Jim Cramer on Bristol-Myers: "Never Seen it This Cheap"

By Syeda Seirut Javed | July 23, 2025, 10:52 AM

Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer reflected on. When asked about the stock during the lightning round, Cramer replied that he is holding out hope for the company’s “central nervous system drug.”

“Bristol Myers, never seen it this cheap. We’re holding it. I did have high hopes for their, what, what I would say is their central nervous system drug. It better work. If it doesn’t work, we’re going to get rid of it, and it will be a disappointment, and it will be a shame.”

Jim Cramer on Bristol-Myers: "Never Seen it This Cheap"

Bristol-Myers (NYSE:BMY) develops and markets biopharmaceutical products targeting cancer, cardiovascular conditions, immune disorders, and neurological diseases. The company’s portfolio includes Eliquis, Opdivo, Revlimid, and other treatments for serious and chronic illnesses. During a June episode, Cramer showed disappointment in the stock, as he commented:

“Bristol Myers, Charitable Trust owns it. So far, we’re not happy with COBENFY. It’s a little disappointing. We need to see that stock back up at 60.”

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.

Mentioned In This Article

Latest News

1 hour
Jul-24
Jul-24
Jul-24
Jul-24
Jul-24
Jul-24
Jul-23
Jul-23
Jul-23
Jul-23
Jul-23
Jul-22
Jul-22
Jul-22